NCT06599216 - Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 8, 2024

Primary Completion Date

March 1, 2026

Study Completion Date

September 1, 2027

Conditions

Breast CancerHR+/HER2- Breast Cancer

Interventions

DRUG

Adebrelimab+Dalpciclib+Standard Endocrine Therapy

Adebrelimab: 1200mg, intravenously, Q4w Dalpiciclib: 150mg once a day for 3 weeks, stop for 1 week, Q4w Standard Endocrine Therapy: Choice of endocrine therapy is according to guidelines and centre policy by investigator

Trial Locations (2)

150081

Harbin Medical Cancer Hospital, Harbin

Unknown

Harbin Medical University Cancer Hospital, Harbin

All Listed Sponsors

lead

Harbin Medical University

OTHER